Search our Database of Scientific Publications and Authors

I’m looking for a

    3310 results match your criteria Prolactinoma

    1 OF 67

    Prolactinoma in a Dog.
    Vet Pathol 2017 Jan 1:300985817726118. Epub 2017 Jan 1.
    6 Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
    A 12-year-old male Yorkshire Terrier was presented because of decreased appetite. Physical examination revealed mammary gland swelling and galactorrhea. Contrast-enhanced computed tomographic scanning of the skull indicated an enlarged pituitary gland, compatible with a pituitary tumor. Read More

    The partner's perspective of the impact of pituitary disease: Looking beyond the patient.
    J Health Psychol 2017 Mar 1:1359105317695427. Epub 2017 Mar 1.
    1 Leiden University Medical Center, The Netherlands.
    People with pituitary disease report impairments in quality of life. The aim of this study was to elucidate the impact of the pituitary condition on the lives of partners. Four focus groups of partners of people with pituitary disease (Cushing's disease, non-functioning adenoma, acromegaly, prolactinoma) were conducted. Read More

    Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review.
    Cancers (Basel) 2017 Aug 8;9(8). Epub 2017 Aug 8.
    Laboratory of Molecular Target Therapy for Cancer, Graduate School for Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
    Pituitary adenomas are often treated with radiotherapy for the management of tumor progression or recurrence. Despite the improvement in cure rates, patients treated by radiotherapy are at risk of development of secondary malignancies. We conducted a comprehensive literature review of the secondary intracranial tumors that occurred following radiotherapy to pituitary adenomas to obtain clinicopathological characteristics. Read More

    Autoimmune hypothyroidism is three times more frequent in female prolactinoma patients compared to healthy women: data from a cross-sectional case-control study.
    Endocrine 2017 Jul 19. Epub 2017 Jul 19.
    University Hospital of Endocrinology, Sofia, Bulgaria.
    Background: The potent immunomodulatory action of prolactin has been demonstrated in many experimental in vitro studies. In accordance with these data, our retrospective analyses revealed higher prevalence of autoimmune thyroid diseases in prolactinoma patients compared to general population.

    Purpose: A cross-sectional case-control study was carried out in a single tertiary referral centre. Read More

    A retrospective review of 34 cases of pediatric pituitary adenoma.
    Childs Nerv Syst 2017 Jul 18. Epub 2017 Jul 18.
    Department of Neurosurgery, West China Hospital, Sichuan University, 37th Guoxue Alley, Chengdu, China.
    Purpose: The purpose of this paper is to study invasiveness, tumor features and clinical symptoms of pediatric pituitary adenoma, and to discuss some inconclusive results in prior studies.

    Methods: We retrospectively reviewed 34 cases of children (<20 year-old) who were pathologically diagnosed with pituitary adenoma and surgically treated from 2010 to 2017. Data of general information, clinical symptoms, invasive behaviors, surgery approaches, and tumor features were collected and analyzed. Read More

    Notch system is differentially expressed and activated in pituitary adenomas of distinct histotype, tumor cell lines and normal pituitaries.
    Oncotarget 2017 Jul 6. Epub 2017 Jul 6.
    Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires, CITNOBA (UNNOBA-CONICET), Universidad Nacional del Noroeste de la Provincia de Buenos Aires, 2700 Buenos Aires, Argentina.
    Pituitary adenomas are among the most frequent intracranial neoplasms and treatment depends on tumor subtype and clinical features. Unfortunately, non responder cases occur, then new molecular targets are needed.Notch system component expression and activation data are scarce in pituitary tumorigenesis, we therefore aimed to characterize Notch system in pituitary tumors of different histotype. Read More

    Best candidates for dopamine agonist withdrawal in patients with prolactinomas.
    Pituitary 2017 Jul 14. Epub 2017 Jul 14.
    Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
    Purpose: Dopamine agonist (DA) therapy is recommended as the first-line treatment for prolactinomas. However, it requires long treatment duration, and a high recurrence rate after DA withdrawal has been reported. We aimed to elucidate the predictors for long-term remission following DA withdrawal and propose the best candidates who can achieve complete remission after DA withdrawal. Read More

    Pregnancy and Tumor Outcomes in Women with Prolactinoma.
    Exp Clin Endocrinol Diabetes 2017 Jul 13. Epub 2017 Jul 13.
    Faculty of Medicine, University of Porto. Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
    Context Management of prolactinomas during pregnancy has always been a challenge. There is a concern about the risk of tumor growth, as well as the effects of the treatment on the developing fetus. Another issue that has been less studied is the outcome of women with prolactinoma after pregnancy and lactation. Read More

    Recent Progress in the Medical Therapy of Pituitary Tumors.
    Endocrinol Metab (Seoul) 2017 Jun;32(2):162-170
    Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
    Management of pituitary tumors is multidisciplinary, with medical therapy playing an increasingly important role. With the exception of prolactin-secreting tumors, surgery is still considered the first-line treatment for the majority of pituitary adenomas. However, medical/pharmacological therapy plays an important role in controlling hormone-producing pituitary adenomas, especially for patients with acromegaly and Cushing disease (CD). Read More

    Menstrual Cycle Abnormalities in Patients with Prolactinoma and Drug-induced Hyperprolactinemia.
    Indian J Endocrinol Metab 2017 Jul-Aug;21(4):545-550
    Department of Endocrinology, PGIMER, Dr. RML Hospital, New Delhi, India.
    Background And Objective: Hyperprolactinemia affects the reproductive endocrine axis; however, the degree of dysfunction may vary depending on etiology. The aim of the present study was to analyze menstrual cyclicity in patients with prolactinoma and drug-induced hyperprolactinemia (DIH).

    Methodology: Patients with prolactinoma and DIH were retrospectively analyzed for menstrual cyclicity at presentation and response to therapy. Read More

    Radiological Growth Patterns of Prolactinomas and Nonfunctioning Adenomas.
    Can J Neurol Sci 2017 Jul 3:1-6. Epub 2017 Jul 3.
    1Division of Endocrinology and Metabolism,Dalhousie University,Halifax,Nova Scotia,Canada.
    Objectives: To compare growth patterns of nonfunctioning and prolactin-producing pituitary macroadenomas, and to find whether their specific growth patterns are associated with clinically significant effects on vision.

    Materials And Methods: From our comprehensive provincial neuropituitary registry, we retrospectively identified 35 randomly selected patients each with nonfunctioning adenomas and prolactinomas >10 mm in any dimension. MRI scans were analyzed to determine the superior and inferior growth, volume, and maximum craniocaudal height of the adenomas. Read More

    How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey.
    J Endocrinol Invest 2017 Jun 20. Epub 2017 Jun 20.
    Department of Endocrinology, Erciyes University Medical School, 38039, Kayseri, Turkey.
    Objective: Data regarding pregnancies in relation to pituitary tumors are limited. The effects of pregnancy on pituitary adenomas and the effects of adenoma itself (hormonal activity, mass effects and pituitary insufficiency) and/or treatment on the ongoing gestation and developing fetus were evaluated.

    Methods: The study was a retrospective study. Read More

    Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes.
    Clin Endocrinol (Oxf) 2017 Jun 19. Epub 2017 Jun 19.
    Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
    Objective: Most prolactinomas in females are diagnosed during the reproductive age, and the majority are microadenomas. Prolactinomas detected in the postmenopausal period are less common with limited published data on their presentation and prognosis. Our objective was to assess the presenting clinical, biochemical and imaging findings, as well as the outcomes of women diagnosed with a prolactinoma in the postmenopausal period. Read More

    Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.
    Autophagy 2017 Jun 14:1-16. Epub 2017 Jun 14.
    a Department of Neurosurgery , First Affiliated Hospital of Wenzhou Medical University , Wenzhou , China.
    Dopamine agonists such as bromocriptine and cabergoline have been successfully used in the treatment of pituitary prolactinomas and other neuroendocrine tumors. However, their therapeutic mechanisms are not fully understood. In this study we demonstrated that DRD5 (dopamine receptor D5) agonists were potent inhibitors of pituitary tumor growth. Read More

    Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors under Temozolomide; Report of Three Cases and Review of the Literature.
    Turk Neurosurg 2017 May 7. Epub 2017 May 7.
    Ankara University Faculty of Medicine, Department of Endocrinology and Metabolism.
    Treatment of aggressive pituitary tumors may be challenging. Temozolomide (TMZ) is a promising agent when conventional treatment methods fail. We present three patients with aggressive pituitary tumors with atypical morphology, who were resistant to conventional treatments and treated with TMZ. Read More

    25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma.
    Endocr Metab Immune Disord Drug Targets 2017 Jun 9. Epub 2017 Jun 9.
    Specialized medical hospital.Mansoua university - laboratory Mansoura, dakahlia. Egypt.
    Objective: The present research explored the relationship of vitamin D status with prolactin levels and adenoma size in female patients with newly diagnosed prolactinoma and determination of hypovitaminosis D prevalence among female patients with prolactinoma.

    Patients And Methods: We enrolled 67 female patients with newly diagnosed prolactinoma (41 with micro adenoma and 26 with macro adenoma) in this case-control study at the time of presentation. We selected a Control Group of 45 female subjects who were matched according to age, weight, height, body mass index and waist circumference. Read More

    Chemiluminescence systems; do all lead to same results in prolactin analysis?
    J Diabetes Metab Disord 2017 5;16:24. Epub 2017 Jun 5.
    Department of Biochemistry, Reference Health Laboratory, Ministry of Health & Medical Education, Tehran, Iran.
    Background: Human prolactin (PRL) is a hormone that is mainly secreted by lactotroph cells of the anterior pituitary gland and is involved in many biological processes including lactation and reproduction. Prolactin level may be determined quantitatively in serum by many different systems including chemiluminescence systems. However, comparison of the measured values between systems is difficult. Read More

    18F-FDOPA PET Imaging in Prolactinoma.
    Clin Nucl Med 2017 Aug;42(8):e383-e384
    From the Departments of *Nuclear Medicine and Nancyclotep Plateform Imaging, †Endocrinology, and ‡Neuroradiology, CHRU-Nancy, Nancy; and §IADI, INSERM U947, Nancy, France.
    Pituitary macroadenoma constitutes a frequently misdiagnosed benign tumor. We report herein a case where such macroadenoma, a prolactinoma, was incidentally discovered in a 63-year-old man who had been referred to F-FDG PET and F-FDOPA PET imaging for a pharmacoresistant epilepsy. An increased uptake was documented for both radiotracers within the sellar region, although with a much higher contrast for F-FDOPA than for F-FDG. Read More

    Korsakoff syndrome from retrochiasmatic suprasellar lesions: rapid reversal after relief of cerebral compression in 4 cases.
    J Neurosurg 2017 Jun 2:1-6. Epub 2017 Jun 2.
    Departments of 1 Neurosurgery and.
    Korsakoff syndrome is a chronic memory disorder caused by a severe deficiency of thiamine that is most commonly observed in alcoholics. However, some have proposed that focal structural lesions disrupting memory circuits-in particular, the mammillary bodies, the mammillothalamic tract, and the anterior thalamus-can give rise to this amnestic syndrome. Here, the authors present 4 patients with reversible Korsakoff syndromes caused by suprasellar retrochiasmatic lesions compressing the mammillary bodies and adjacent caudal hypothalamic structures. Read More

    'Coexisting pituitary adenoma and suprasellar meningioma-a coincidence or causation effect: report of two cases and review of the literature'.
    J Surg Case Rep 2017 May 22;2017(5):rjx039. Epub 2017 May 22.
    Department of Neurosurgery, Sina Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
    Coexistence of pituitary adenoma (PA) and another type of brain tumor is a very rare clinical scenario. Even though such a presentation can be an incidental event but a thorough review of the literature will be made to elucidate the possible mechanisms and treatment options in similar cases. Two cases of concomitant sellar and suprasellar/diaphragmatic tumors are reported. Read More

    MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors.
    Endocrine 2017 May 22. Epub 2017 May 22.
    Department of Surgery and Translational Medicine, University of Florence, Largo Palagi 1, 50139, Florence, Italy.
    Purpose: To retrospectively evaluate the age of onset of MEN1-associated lesions in a group of affected children and adolescents and to compare the clinical features of our series with the evidence derived from the literature.

    Methods: The study population consisted of 22 Italian children and adolescents (age 6-31 years at the time of the inclusion in this study) all with a clinical and/or a genetic diagnosis of MEN1 performed before the age of 16 who have been followed-up regularly from 1998 to 2016 at the Regional Referral Center for Hereditary Endocrine Tumors. Clinical, biochemical, imaging and genetic data have been collected for each patient. Read More

    Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
    Pituitary 2017 Aug;20(4):464-470
    Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319, Porto, Portugal.
    Objective: Prolactinomas are the most common functional pituitary tumour. Dopamine agonists (DA) are its principal treatment. The criteria that should guide therapy withdrawal and the factors that influence disease remission or relapse are not yet fully established. Read More

    Fertility, pregnancy, and prolactinoma: A survey of pituitary surgeons' view and review of the literature.
    J Clin Neurosci 2017 Aug 13;42:198-203. Epub 2017 May 13.
    Department of Neurosurgery, Georgetown University, United States.
    Objective: Pituitary surgeons frequently encounter female prolactinoma patients seeking treatment to restore fertility. Current medical guidelines recommend using dopamine agonist (DA) for this, but for fetal safety, DA should stop upon pregnancy confirmation. The probability that prolactinoma may grow during pregnancy makes this last recommendation imperfect. Read More

    [Effect of metformin on proliferation and apoptosis of rat prolactinoma MMQ cells and related mechanisms].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2017 May;33(5):643-648
    Department of Neurosurgery, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China. *Corresponding author, E-mail:
    Objective To investigate the effect of metformin on the cell proliferation, cell cycle and apoptosis of rat prolactinoma MMQ cells in vitro and related molecular mechanisms. Methods The MMQ cells were treated with 1.25, 2. Read More

    Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines.
    Oncotarget 2017 Jul;8(28):45874-45887
    Department of Histology and Embryology, Medical School of Sun Yat-Sen University, Guangzhou, China.
    Prolactinomas are the most prevalent functional pituitary adenomas. The preferred treatments for prolactinomas are dopamine agonists (DAs) such as bromocriptine (BRC), but DAs still have the challenges of tumor recurrence and drug resistance. This study demonstrates that the synergy of function and mechanism between artesunate (ART) and BRC inhibits prolactinoma cell growth in vitro. Read More

    Synergistic Inhibition of Delayed Rectifier K+ and Voltage-Gated Na+ Currents by Artemisinin in Pituitary Tumor (GH3) Cells.
    Cell Physiol Biochem 2017 14;41(5):2053-2066. Epub 2017 Apr 14.
    Department of Physiology, National Cheng Kung University Medical College, Tainan City, Taiwan.
    Background: Artemisinin (ART) is an anti-malarial agent reported to influence endocrine function.

    Methods: Effects of ART on ionic currents and action potentials (APs) in pituitary tumor (GH3) cells were evaluated by patch clamp techniques.

    Results: ART inhibited the amplitude of delayed-rectifier K+ current (IK(DR)) in response to membrane depolarization and accelerated the process of current inactivation. Read More

    Comparison of MRI techniques for detecting microadenomas in Cushing's disease.
    J Neurosurg 2017 Apr 28:1-7. Epub 2017 Apr 28.
    Department of Neurological Surgery and.
    OBJECTIVE Many centers use conventional and dynamic contrast-enhanced MRI (DMRI) sequences in patients with Cushing's disease. The authors assessed the utility of the 3D volumetric interpolated breath-hold examination, a spoiled-gradient echo 3D T1 sequence (SGE) characterized by superior soft tissue contrast and improved resolution, compared with DMRI and conventional MRI (CMRI) for detecting microadenomas in patients with Cushing's disease. METHODS This study was a blinded assessment of pituitary MRI in patients with proven Cushing's disease. Read More

    The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage.
    In Vivo 2017 May-Jun;31(3):357-363
    Department of Endocrinology and Metabolism, Bezmialem Vakif University, Istanbul, Turkey.
    Aim: Prolactinomas are thought to arise from clonal expansion of a single mutated cell which is subjected to growth stimuli of several permissive factors, although the pathogenetic mechanisms underlying tumorigenesis remain unclear. The present study aimed to investigate the role of p16 (540C→G and 580C→T) and mouse double minute 2 (MDM2) (SNP309T→G) gene polymorphisms in tumorigenesis and characteristics of prolactinoma.

    Patients And Methods: A total of 74 patients with prolactinoma and 100 age- and gender-matched healthy individuals were enrolled in the study. Read More

    Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
    Med Sci Monit 2017 Apr 23;23:1947-1955. Epub 2017 Apr 23.
    Department of Clinical Laboratory, People's Hospital of Weifang, Weifang, Shandong, China (mainland).
    BACKGROUND Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism. Somatostatin analogs have proved to be effective for inhibiting pituitary hormones secretion, working via interactions with somatostatin receptors (SSTRs). Moreover, antiproliferative activity of somatostatin analog is now demonstrated in several studies. Read More

    Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
    Eur J Endocrinol 2017 Jun;176(6):769-777
    Fédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
    Objectives: Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated patients is rarely evaluated. We therefore aimed to describe the use of TMZ on PT in clinical practice and evaluate the long-term survival. Read More

    A novel "total pituitary hormone index" as an indicator of postoperative pituitary function in patients undergoing resection of pituitary adenomas.
    Oncotarget 2017 Mar 7. Epub 2017 Mar 7.
    Department of Neurosurgery, Fuzhou General Hospital, Fujian Medical University, Fuzhou, P. R. China.
    The purpose of this study was to investigate the differences between pre- and postoperative pituitary hormone levels in patients undergoing surgical resection of pituitary adenoma and to identify factors associated with preoperative hypopituitarism.Data from 81 patients with histologically confirmed functioning and non-functioning pituitary adenomas (NFPA) who underwent transsphenoidal resection from January 2011 to December 2013 were retrospectively analyzed. Logistic regression was applied to analyze factors associated with preoperative hypopituitarism. Read More

    Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
    Med Sci Monit 2017 Apr 15;23:1827-1833. Epub 2017 Apr 15.
    Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China (mainland).
    BACKGROUND Dopamine agonists (DAs) are the first-line treatment for prolactinomas. DAs primarily target the dopamine D2 receptor (D2R). Tumor stem-like cells (TSLCs) are associated with the tolerance to radiotherapy and chemotherapy. Read More

    Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms.
    J Ethnopharmacol 2017 May 7;204:36-44. Epub 2017 Apr 7.
    Endocrinology and Metabolism Group, Sydney Institute of Health Sciences/Sydney Institute of Traditional Chinese Medicine, NSW 2000, Australia. Electronic address:
    Ethnopharmacological Relevance: Paeoniflorin and liquiritin are major constituents in some Chinese herbal formulas, such as Yiru Tiaojing (YRTJ) Granule (a hospitalized preparation) and Peony-Glycyrrhiza Decoction, used for hyperprolactinemia-associated disorders.

    Aim Of The Study: To investigate the effect of paeoniflorin and liquiritin on prolactin secretion.

    Materials And Methods: The effect of YRTJ Granule on metoclopramide-induced hyperprolactinemia was tested in rats. Read More

    N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma.
    Diagn Pathol 2017 Apr 8;12(1):33. Epub 2017 Apr 8.
    Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str.4, LT-50009, Kaunas, Lithuania.
    Background: Pituitary adenoma (PA) is a benign primary tumor that arises from the pituitary gland and is associated with ophthalmological, neurological and endocrinological abnormalities. However, causes that increase tumor progressing recurrence and invasiveness are still undetermined. Several studies have shown N-myc downstream regulated gene 2 (NDRG2) as a tumor suppressor gene, but the role of NDRG2 gene in pituitary adenoma pathogenesis has not been elucidated. Read More

    Progressive visual disturbance and enlarging prolactinoma caused by melanoma metastasis: A case report and literature review.
    Medicine (Baltimore) 2017 Apr;96(14):e6483
    aDepartment of Neurosurgery of the Second Affiliated Hospital bInstitute of Cancer Stem Cell cDepartment of Endocrinology of Affiliated Dalian Municipal Central Hospital, Dalian Medical University, Dalian, Liaoning Province dDepartment of Neurosurgery of Yantaishan Hospital, Yantai, Shandong Province, PR China.
    Rationale: Melanoma metastases to the pituitary adenoma (MMPA) are extremely rare, with only 1 reported case. To date, the melanoma metastasis to the existing prolactinoma has not been reported in literatures.

    Patient Concerns: We report a case of 62-year-old woman presented with progressive visual disturbance and hyperprolactinemia. Read More

    Xanthogranuloma of the sellar region diagnosed by frozen section.
    Open Med (Wars) 2016 11;11(1):426-428. Epub 2016 Nov 11.
    Departments of Neurosurgery, The Second Clinical Medical School of Inner Mongolia University for the Nationalities (Inner Mongolia General Forestry Hospital), Yakeshi 022150, Inner Mongolia, China.
    Xanthogranuloma (XG) of the sellar region is uncommon and is difficult to diagnose based on intraoperative frozen sections. This study is a case presentation and review of the literature, highlighting the need to explore underlying diseases in order to guarantee an accurate patient diagnosis. Herein, we presented the case of a 43-year-old woman who was afflicted with xanthogranuloma of the sellar region; the patient had a history of headache and lengthened menstrual cycles over the 6 months prior to presentation. Read More

    Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas.
    J Neurol Surg B Skull Base 2017 Apr 27;78(2):125-131. Epub 2016 Sep 27.
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, California, United States.
    Background Few studies address the cost of treating prolactinomas. We performed a cost-utility analysis of surgical versus medical treatment for prolactinomas. Materials and Methods We determined total hospital costs for surgically and medically treated prolactinoma patients. Read More

    Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis.
    Case Rep Endocrinol 2017 22;2017:3974291. Epub 2017 Feb 22.
    General Surgery Department, Liv Hospital, Ulus, Istanbul, Turkey.
    Idiopathic granulomatous mastitis (IGM) is a rare chronic inflammatory disease of the breast, and its etiology remains not fully elucidated. IGM is observed more often in patients with autoimmune disease. Hyperprolactinemia is observed during pregnancy, lactation, and a history of oral contraceptive use. Read More

    Breast carcinoma associated with prolactinoma: A case report.
    Cancer Biol Ther 2017 Mar 17;18(3):132-136. Epub 2017 Feb 17.
    a Department of Breast Surgery , Zhejiang Cancer Hospital , Hangzhou , China.
    We report a 28-year-old woman who presented with a 6-year history of milk-like discharge from both of her nipples and was diagnosed with prolactinoma based on computed tomography (CT) findings and serum prolactin level. Further breast examination revealed a mass located in the upper outer region of the left breast. She underwent subtotal pituitary tumor resection. Read More

    Therapeutic effects of Schisandra chinensis on the hyperprolactinemia in rat.
    Int J Oncol 2017 Apr 17;50(4):1448-1454. Epub 2017 Feb 17.
    Department of Biomaterials Science, College of Natural Resources and Life Science, Pusan National University, Miryang‑si, Gyeongsangnam‑do, Republic of Korea.
    Prolactin (PRL) is secreted from the pituitary gland in response to eating, mating, and ovulation. Increased serum concentration of PRL during pregnancy contributes to enlargement of the mammary glands of the breasts and prepares for production of milk. However, high PRL levels derived from prolactinoma and hyperprolactinemia induce physiological disorders such as infertility and early menopause. Read More

    Clozapine Treatment for Cabergoline-Induced Psychosis in a Patient With a Giant Prolactinoma.
    J Neuropsychiatry Clin Neurosci 2017 27;29(3):295-297. Epub 2017 Feb 27.
    From the Department of Neuropsychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico (RP-E, PA-G, JR-B); the Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico (RP-E); and the Department of Neuroendocrinology, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico (CAR-G, GGA-R, LP-O).

    Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.
    Indian J Endocrinol Metab 2017 Jan-Feb;21(1):154-159
    Department of Endocrinology, Seth G S Medical College and KEM Hospital, Mumbai, Maharashtra, India.
    Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear.

    Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking cabergoline for the treatment of prolactinoma and to explore any associations with the cumulative dose of drug used.

    Design: A cross-sectional echocardiographic study was performed in patients who were receiving cabergoline therapy for prolactinoma. Read More

    Cluster headache and macroprolactinoma: Case report of a rare, but potential important causality.
    J Clin Neurosci 2017 Jun 10;40:62-64. Epub 2017 Feb 10.
    Department of Endocrinology, Universtiy Hospital Basel, University of Basel, Basel, Switzerland. Electronic address:
    While headache is not an uncommon symptom in patients suffering from pituitary adenomas, cluster headache (CH) has rarely been reported in such cases. Headache associated with hyperprolactinemia has been reported to be responsive to dopamine agonists (DA agonists) in many patients. We report on a patient with refractory CH secondary to a macroprolactinoma who showed immediate and permanent clinical and radiologic recovery following medical treatment with DA agonists. Read More

    Giant Prolactinoma Presenting As a Base of Skull Tumor With Nasopharyngeal Extension: A Potential Diagnostic Pitfall in Neuroendocrine Lesions of the Base of Skull.
    Head Neck Pathol 2017 Feb 14. Epub 2017 Feb 14.
    Department of Pathology, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
    Pituitary adenomas presenting in uncommon anatomical locations are commonly misdiagnosed. Dramatic clinical presentation with hemorrhage and infarction, along with a lack of endocrine symptoms may further confound the diagnosis in some patients as illustrated in one of our two previously reported cases of non-small cell neuroendocrine carcinoma of the sinonasal tract and nasopharynx. This report presents the clinical progress of case number 2, which has a revised diagnosis of giant lactotroph pituitary adenoma. Read More

    Diagnosis and Treatment of Pituitary Adenomas: A Review.
    JAMA 2017 Feb;317(5):516-524
    Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
    Importance: Pituitary adenomas may hypersecrete hormones or cause mass effects. Therefore, early diagnosis and treatment are important.

    Observations: Prevalence of pituitary adenomas ranges from 1 in 865 adults to 1 in 2688 adults. Read More

    Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell.
    Cancer Cell Int 2017 31;17:15. Epub 2017 Jan 31.
    Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100050 China.
    Background: Cancer stem cells (CSCs), which have been isolated from various malignancies, were closely correlated with the occurrence, progression, metastasis and recurrence of the malignant cancer. Little is known about the tumor stem-like cells (TSLCs) isolated from benign tumors. Here we want to explore the global expression profile of RNA of tumor stem-like cells isolated from MMQ rat prolactinoma cells. Read More

    An Economic Analysis of Bromocriptine Versus Trans-Sphenoidal Surgery for the Treatment of Prolactinoma.
    J Craniofac Surg 2017 Jun;28(4):1046-1051
    *Key Laboratory of Endocrinology, Ministry of Health; Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences †Department of Clinical Medicine, Peking Union Medical College ‡Department of National Health Accounts and Policy Studies, China National Health Development Research Center, Beijing, China.
    Prolactinomas account for ∼40% of all pituitary adenomas and are important causes of infertility and gonadal dysfunction. In general, most prolactinomas are treated medically with dopaminergic agonists, while surgery is reserved for patients intolerant or nonresponsive to these medications. The aim of this study was to carry out a comparative analysis of the cost-effectiveness of medical therapy with bromocriptine and surgical therapy with trans-sphenoidal surgery. Read More

    1 OF 67